Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful-Reference-Cited by-同舟云学术

Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful

Published:2018-12 Issue:6 Volume:67 Page:745-748
ISSN:0277-2116
Container-title:Journal of Pediatric Gastroenterology & Nutrition
language:en
Short-container-title:

Author:

Gervais Lisa,McLean Luke L.,Wilson Michelle L.,Cameron Carol,Curtis Lee,Garrick Vikki,Armstrong Kat,Tayler Rachel,Henderson Paul,Hansen Richard,Chalmers Iain,Wilson David C.,Russell Richard K.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Pediatrics, Perinatology and Child Health

Reference14 articles.

1. Corrigendum: third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management;Harbord;J Crohn Colitis,2017

2. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease. Part 1: diagnosis and medical management;Gomollon;J Crohn Colitis,2017

3. Biosimilar infliximab use in paediatric IBD;Richmond;Arch Dis Child,2018

4. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumor necrosis factor-α agent (infliximab), in inflammatory bowel diseases;Kamaki;Aliment Pharmacol Ther,2017

5. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial;Jorgensen;Lancet,2017

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents;Saudi Journal of Gastroenterology;2024-08-30

2. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-07-02

3. Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease;Frontiers in Immunology;2024-02-22

4. Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease;Journal of Pediatric Gastroenterology and Nutrition;2024-02-09

5. Factors that influence infliximab biosimilar trough levels in the pediatric inflammatory bowel disease population;Expert Review of Clinical Immunology;2023-11-18